GSK logo linking to the homepage Menu Tackling diseases in developing countries We work to tackle some of the root causes of disease and ill-health and contribute to healthier communities around the world. We are one of the few companies researching treatments and vaccines for all three of the World Health Organization’s priority infectious diseases: malaria, tuberculosis and HIV. In developing countries, people affected by certain diseases face stigma and discrimination, disability and a vicious cycle of ill health and poverty. Diseases that can be prevented, managed, or cured cause significant suffering and mortality due to a lack of basic knowledge and inadequate health services. Edou Komlan, a lymphatic filarisis patient and his family We support activities to tackle these diseases through donations of medicines, financial and practical support. Our global health programmes focus on malaria, lymphatic filariasis and intestinal worms in partnership with governments, NGOs and other organisations to maximise benefits for communities. We also collaborate closely with United Nations Children’s Fund (UNICEF), the World Health Organisation (WHO), Pan American Health Organization (PAHO) and financing agencies such as the Global Alliance for Vaccines and Immunisation (GAVI) to support the introduction of vaccines once they are available. GSK is the leading vaccine supplier to organisations such as UNICEF and the PAHO and we provide vaccines to help protect children and babies from infectious diseases including pneumococcal disease, rotavirus gastroenteritis, meningitis, pertussis (whooping cough), measles, polio, mumps and rubella. Malaria Neglected tropical diseases Hygiene education The fight against malaria Malaria is responsible for more than 550,000 deaths a year and around 3.2 billion people are at risk. Spread by mosquitos, around 90% of estimated deaths from malaria occur in Sub-Saharan Africa (SSA), and 77% of these are in children under the age of 5. The human cost is enormous, as is the economic cost – malaria consumes around 40% of all public health expenditure in endemic countries. We are playing a significant role to improve the health of communities affected by malaria in three ways: researching new malaria medicines, treatments and vaccines pricing our anti-malarials in the least developed countries and sub-Saharan Africa affordably investing in community activities funded by our partnership with Comic Relief Partnership No one organisation has the ability to defeat malaria on its own. That’s why we are working in partnership with other organisations to develop new tools whilst increasing the use of existing methods like bed nets and indoor spraying of insecticides. In 2017, we continued our partnerships with Amref Health Africa and Save the Children to train health professionals and community health workers in Tanzania and Kenya respectively, with FHI 360 and The Carter Center to combine interventions, control malaria and NTDs in Ghana and Nigeria, and with the Faiths Act Sierra Leone to train faith leaders to become malaria ambassadors. Through our partnership with Comic Relief, a UK charity, we are aiming to fight malaria and strengthen health systems. The £22 million partnership, created by a £17 million donation from GSK and £5 million from Comic Relief, makes grants to frontline organisations in five malaria endemic countries. This complements interventions by other global health funders and grassroots organisations. Projects range from youth-led approaches to increase malaria awareness, to training of frontline community healthcare workers and volunteers. Through these collaborations, we aim to support the WHO target to reduce malaria cases and deaths by at least 90% by 2030 and support the Global Goals for Sustainable Development. Back to top GSK Quick links Behind the science About us Products Careers Investors Media Research Responsibility Legal Terms of use Cookie policy Privacy Notice Modern Slavery Act statement 2017 PDF - 199.6KB Accessibility Sitemap Accessibility Contact us Contact us Partnerships Report a possible side effect Business to business Supplier website Business to business © 2001-2018 GlaxoSmithKline plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies. GlaxoSmithKline plc. Registered in England and Wales No. 3888792. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.